Can COVID‐19 immunisation cause subacute thyroiditis?

Ratnayake, Gowri; Dworakowska, Dorota; Grossman, Ashley

doi:10.1111/cen.14555

Cited by 31 publications

(23 citation statements)

References 12 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recently, several SAT cases appearing 1–21 days (median seven days) after SARS-CoV-2 vaccination was reported [ 25 – 34 ]. Median period was four weeks (1–12 weeks) for our six cases in Vac-SAT group.…”

Section: Discussionmentioning

confidence: 99%

Subacute thyroiditis during the COVID-19 pandemic: a prospective study

Mutlu

Karahan

Aydoğan

et al. 2022

J Endocrinol Invest

View full text Add to dashboard Cite

Purpose Subacute thyroiditis(SAT) is a destructive thyroiditis associated with viral infections. Several SAT cases associated with SARS-CoV-2 infection/vaccination were recently reported. We aimed to evaluate prospectively all cases applied to our tertiary center and their relationship with SARS-CoV-2 during 16 months of the pandemic. Cases during similar pre-pandemic period were recorded for numeric comparison. Methods Prospective study took place between March 2020 and July 2021. SAT was diagnosed by classical criteria. Swabs for SARS-CoV-2 and a wide respiratory viral panel (RV-PCR) were taken. Previous COVID-19 was assessed by SARS-CoV-2 IgM&IgG levels. Study group was divided into three as: CoV-SAT, patients who had or still have COVID-19, Vac-SAT, patients diagnosed within three months after SARS-CoV-2 vaccination and NonCoV-SAT, those not associated with COVID-19 or vaccination. Results Out of 64 patients, 18.8% ( n = 12) was classified as CoV-SAT, 9.3% ( n = 6) as Vac-SAT and 71.9% as ( n = 46) NonCoV-SAT. SARS-CoV-2 RT-PCR tests on the diagnosis of SAT were negative in all, but two patients tested positive five days later, in second testing, performed upon clinical necessity. CoV-SAT and NonCoV-SAT groups were similar in terms of clinical, laboratory, and treatment characteristics. However, symptoms were milder and treatment was easier in Vac-SAT group ( p = 0.006). Conclusions Total number of SAT cases during the pandemic period was comparable to pre-pandemic period. However, a considerable rate of SARS-CoV-2 exposure in SAT patients was established. COVID-19 presented with SAT, as the first manifestation in three cases. Vaccine-related cases developed in a shorter time period, clinical presentation was milder, and only a few required corticosteroids.

show abstract

Section: Discussionmentioning

confidence: 99%

Subacute thyroiditis during the COVID-19 pandemic: a prospective study

Mutlu

Karahan

Aydoğan

et al. 2022

J Endocrinol Invest

View full text Add to dashboard Cite

show abstract

“…Recently, following the massive vaccination programme worldwide, there have been a few reports of thyroid dysfunction after SARS-CoV-2 vaccination, including SAT [ [13] , [14] , [15] , [16] , [17] , [18] , [19] , [20] , [21] , [22] , [23] , [24] , [25] , [26] , [27] , [28] ] and Graves' disease [ 19 , [29] , [30] , [31] ]. All types of vaccines have been involved, namely inactivated virus SARS-CoV-2 vaccines CORONAVAC [ [13] , [14] , [15] ] and COVAXIN [ 21 ], viral vector-based vaccines VAXZEVRIA [ [16] , [17] , [18] , [19] , [20] , 31 ] and Janssen [ 19 ] and mRNA-based vaccines COMIRNATY [ [22] , [23] , [24] , [25] , [26] , [27] , [28] ] and MODERNA [ 20 ].…”

Section: Discussionmentioning

confidence: 99%

“…In addition, SAT has been described following influenza or hepatitis B vaccination [ [7] , [8] , [9] , [10] , [11] , [12] ]. Recently, cases have been reported of SAT following SARS-CoV-2 vaccination with CoronaVac (Sinovac Life Sciences, China) [ [13] , [14] , [15] ], Vaxzevria (AstraZeneca, Sweden) [ [16] , [17] , [18] , [19] , [20] ], Spikevax (Moderna Biotech, Spain) [ 20 ], Covaxin (Bharat Biotech, India) [ 21 ], and Pfizer-BioNTech SARS-CoV-2 mRNA vaccine (BioNTech, Fosun Pharma, Pfizer, Germany and USA) [ [22] , [23] , [24] , [25] , [26] , [27] , [28] ].…”

Section: Introductionmentioning

confidence: 99%

Recurring subacute thyroiditis after SARS-CoV-2 mRNA vaccine: A case report

Vasileiou

Paschou

Tzamali

et al. 2022

Case Reports in Women's Health

View full text Add to dashboard Cite

SARS-CoV-2 vaccination is the most powerful and promising tool against the COVID-19 pandemic. Millions of people have been vaccinated worldwide. Recently, few cases of subacute thyroiditis following SARS-CoV-2 vaccination with various types of vaccine have been reported of subacute thyroiditis following SARS-CoV-2 vaccination with various types of vaccine. We describe here a 36-year-old woman who presented with subacute thyroiditis 10 days after she had received her first dose of the SARS-CoV-2 mRNA vaccine Comirnaty (Pfizer/BioNTech); the condition receded but then recurred 10 days after she received her second dose. As vaccination programmes proceed, clinicians' attention and vigilance for such cases will be increased. Physicians need to know that subacute thyroiditis is a mild and self-limiting condition in the majority of cases. Last but not least, the benefits of vaccination against COVID-19 outweigh the side-effects reported so far.

show abstract

“…A small number of cases of subacute thyroiditis following SARS-CoV-2 vaccination have been reported recently ( 6 , 7 , 8 , 9 , 10 , 11 ). Only one previous case of subacute thyroiditis post-Pfizer-BioNTech vaccine has been described in the literature with clinical and biochemical improvement in symptoms after a short course of anti-inflammatory therapy ( 6 ).…”

Section: Discussionmentioning

confidence: 99%

“…Two more cases of subacute thyroiditis have been described after SARS-CoV-2 vaccination with Moderna Biotech and AstraZeneca ( 10 ). One other case has been described post-AstraZeneca vaccine, which contains recombinant replication-deficient chimpanzee adenovirus vector encoding the SARS CoV-2 spike glycoprotein ( 11 ).…”

Section: Discussionmentioning

confidence: 99%

Subacute thyroiditis post-Pfizer-BioNTech mRNA vaccination for COVID-19

Khan

Brassill

2021

Endocrinology, Diabetes &Amp; Metabolism Case Reports

View full text Add to dashboard Cite

Summary There is emerging evidence of an association between COVID-19 vaccination and subacute thyroiditis. We present the case of a 42-year-old female healthcare worker who was diagnosed with subacute thyroiditis 4 days after receiving her second dose of Pfizer-BioNTech vaccine. Her clinical course followed the classical pattern for thyroiditis with spontaneous return to euthyroidism at 6 months post-presentation. The autoimmune/inflammatory syndrome induced by adjuvants has been implicated as a cause of autoimmune conditions post-vaccination and is a potential mechanism for subacute thyroiditis in our case. Learning points Subacute thyroiditis should be considered in all patients who receive any kind of vaccine for COVID-19 and subsequently develop symptoms or signs of hyperthyroidism or neck pain. Subacute thyroiditis is a self-limiting condition, and recognising it is important as no specific thyroid treatment (antithyroid drugs or thyroid hormone replacement) is necessary for most patients. The autoimmune/inflammatory syndrome induced by adjuvants may be an under-recognised cause of endocrinopathies and should particularly be considered post-vaccination.

show abstract

Can COVID‐19 immunisation cause subacute thyroiditis?

Cited by 31 publications

References 12 publications

Subacute thyroiditis during the COVID-19 pandemic: a prospective study

Subacute thyroiditis during the COVID-19 pandemic: a prospective study

Recurring subacute thyroiditis after SARS-CoV-2 mRNA vaccine: A case report

Subacute thyroiditis post-Pfizer-BioNTech mRNA vaccination for COVID-19

Contact Info

Product

Resources

About